Immuneering (IMRX) News Today $1.80 +0.10 (+5.56%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$1.78 -0.02 (-1.39%) As of 02/21/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Critical Review: Immuneering (NASDAQ:IMRX) and Alkermes (NASDAQ:ALKS)February 16, 2025 | americanbankingnews.comImmuneering (NASDAQ:IMRX) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $12.00 price objective on shares of Immuneering in a research note on Thursday.February 6, 2025 | marketbeat.comImmuneering and Regeneron partner on lung cancer trialFebruary 6, 2025 | msn.comImmuneering Announces Clinical Supply Agreement with Regeneron Pharmaceuticals to Evaluate IMM-1-104 in Combination with Libtayo® (cemiplimab)February 6, 2025 | finance.yahoo.comImmuneering Signs Clinical Supply Agreement With Regeneron To Evaluate IMM-1-104 Plus LibtayoFebruary 6, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and Palatin Technologies (PTN)February 6, 2025 | markets.businessinsider.comImmuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences ConferenceFebruary 3, 2025 | globenewswire.comImmuneering Co. (NASDAQ:IMRX) Receives Average Recommendation of "Hold" from AnalystsImmuneering Co. (NASDAQ:IMRX - Get Free Report) has been assigned an average rating of "Hold" from the eight research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have given a hold rating and four have issued aFebruary 3, 2025 | marketbeat.comImmuneering Co. (NASDAQ:IMRX) Short Interest UpdateImmuneering Co. (NASDAQ:IMRX - Get Free Report) was the target of a large decrease in short interest in January. As of January 15th, there was short interest totalling 1,760,000 shares, a decrease of 23.1% from the December 31st total of 2,290,000 shares. Approximately 7.9% of the company's shares are short sold. Based on an average trading volume of 2,290,000 shares, the short-interest ratio is presently 0.8 days.January 30, 2025 | marketbeat.comShort Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 23.1%Immuneering Co. (NASDAQ:IMRX - Get Free Report) was the target of a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 1,760,000 shares, a decline of 23.1% from the December 15th total of 2,290,000 shares. Approximately 7.9% of the shares of the company are sold short. Based on an average daily volume of 2,290,000 shares, the short-interest ratio is presently 0.8 days.January 16, 2025 | marketbeat.comImmuneering Updates On Positive Phase 2a Results For IMM-1-104 With Modified FOLFIRINOXJanuary 14, 2025 | markets.businessinsider.comMorgan Stanley Sticks to Their Sell Rating for Immuneering (IMRX)January 14, 2025 | markets.businessinsider.comImmuneering (NASDAQ:IMRX) Given Buy Rating at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $15.00 price objective on shares of Immuneering in a report on Monday.January 13, 2025 | marketbeat.comImmuneering Provides Positive Update on Phase 2a Arm Studying IMM-1-104 in Combination with Modified FOLFIRINOX for First-Line Pancreatic CancerJanuary 13, 2025 | finance.yahoo.comImmuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Hold" from BrokeragesImmuneering Co. (NASDAQ:IMRX - Get Free Report) has earned an average recommendation of "Hold" from the eight ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendaJanuary 9, 2025 | marketbeat.comImmuneering (NASDAQ:IMRX) Given "Buy" Rating at Chardan CapitalChardan Capital reaffirmed a "buy" rating and set a $13.00 price objective on shares of Immuneering in a report on Wednesday.January 8, 2025 | marketbeat.comImmuneering Gets Encouraging Data From Ongoing IMM-1-104 Trial For Pancreatic Cancer TreatmentJanuary 7, 2025 | markets.businessinsider.comImmuneering stock soars on promising pancreatic cancer trial resultsJanuary 7, 2025 | au.investing.comImmuneering announce data update from Phase 2a trial of IMM-1-104January 7, 2025 | markets.businessinsider.comImmuneering’s Promising Combination Therapies Drive Buy Rating Amidst Strong Pancreatic Cancer Trial ResultsJanuary 7, 2025 | markets.businessinsider.comImmuneering expands lead program after favorable mid-stage data in pancreatic cancerJanuary 7, 2025 | msn.comImmuneering's (IMRX) Buy Rating Reiterated at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and set a $15.00 target price on shares of Immuneering in a research note on Tuesday.January 7, 2025 | marketbeat.comWhy Is Immuneering Stock Trading Higher On Tuesday?January 7, 2025 | benzinga.comTop 5 Biotech Stocks That Captured Retail Investor Interest The Most In 2024December 26, 2024 | msn.comImmuneering Launches Pancreatic Cancer Advisory BoardDecember 19, 2024 | globenewswire.comImmuneering to Present Data from Three Arms of its Ongoing Phase 2a Trial of IMM-1-104 in Early January 2025December 17, 2024 | markets.businessinsider.comImmuneering Co. (NASDAQ:IMRX) Given Average Recommendation of "Hold" by AnalystsShares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have been given a consensus rating of "Hold" by the eight brokerages that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and fourDecember 15, 2024 | marketbeat.comMorgan Stanley upgrades PTC, cuts Immuneering, AmicusDecember 13, 2024 | msn.comImmuneering (NASDAQ:IMRX) Lowered to Underweight Rating by Morgan StanleyMorgan Stanley downgraded shares of Immuneering from an "equal weight" rating to an "underweight" rating in a research report on Friday.December 13, 2024 | marketbeat.comImmuneering granted FDA Fast Track designation for IMM-1-104December 12, 2024 | markets.businessinsider.comImmuneering Corporation: Immuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced MelanomaDecember 12, 2024 | finanznachrichten.deImmuneering Granted FDA Fast Track Designation for IMM-1-104 in Advanced MelanomaDecember 12, 2024 | globenewswire.comImmuneering to Present at the Piper Sandler 36?? Annual Healthcare ConferenceNovember 27, 2024 | tmcnet.comImmuneering to Present at the Piper Sandler 36ᵗʰ Annual Healthcare ConferenceNovember 27, 2024 | globenewswire.comImmuneering Co. (NASDAQ:IMRX) Given Consensus Recommendation of "Moderate Buy" by BrokeragesShares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold rating and four have issued a buy ratinNovember 20, 2024 | marketbeat.comImmuneering Corp. Reports Q3 Loss, Highlights ProgressNovember 16, 2024 | markets.businessinsider.comImmuneering’s Promising Outlook: Strong Clinical Progress and Financial StabilityNovember 15, 2024 | markets.businessinsider.comCautious Hold Recommendation on Immuneering Amid Promising Developments and Financial UncertaintiesNovember 15, 2024 | markets.businessinsider.comImmuneering's (IMRX) "Buy" Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and set a $15.00 target price on shares of Immuneering in a research report on Thursday.November 14, 2024 | marketbeat.comImmuneering Reports Third Quarter 2024 Financial Results and Provides Business UpdatesNovember 13, 2024 | globenewswire.comShort Interest in Immuneering Co. (NASDAQ:IMRX) Declines By 6.7%Immuneering Co. (NASDAQ:IMRX - Get Free Report) saw a significant decrease in short interest during the month of October. As of October 15th, there was short interest totalling 1,520,000 shares, a decrease of 6.7% from the September 30th total of 1,630,000 shares. Based on an average daily volume of 6,690,000 shares, the days-to-cover ratio is presently 0.2 days. Approximately 7.2% of the shares of the company are short sold.October 31, 2024 | marketbeat.comImmuneering Co. (NASDAQ:IMRX) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesShares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold rating and four have given a buyOctober 26, 2024 | marketbeat.comBiotech Shares Rip Following FDA Designation AnnouncementOctober 16, 2024 | theglobeandmail.comImmuneering Granted Orphan Drug Designation for IMM-1-104 by FDA in the Treatment of Pancreatic CancerOctober 15, 2024 | markets.businessinsider.comHere's Why We're A Bit Worried About Immuneering's (NASDAQ:IMRX) Cash Burn SituationOctober 14, 2024 | finance.yahoo.comRenaissance Technologies LLC Takes Position in Immuneering Co. (NASDAQ:IMRX)Renaissance Technologies LLC purchased a new position in shares of Immuneering Co. (NASDAQ:IMRX - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 349,100 shares of the company's stock, valued at approximately $447,0October 11, 2024 | marketbeat.com384,075 Shares in Immuneering Co. (NASDAQ:IMRX) Purchased by Marshall Wace LLPMarshall Wace LLP purchased a new position in Immuneering Co. (NASDAQ:IMRX - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 384,075 shares of the company's stock, valueOctober 10, 2024 | marketbeat.comImmuneering Co. (NASDAQ:IMRX) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Immuneering Co. (NASDAQ:IMRX - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven brokerages that are presently covering the company, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation and four have issued aOctober 1, 2024 | marketbeat.comImmuneering Co. (NASDAQ:IMRX) Short Interest Up 98.7% in SeptemberImmuneering Co. (NASDAQ:IMRX - Get Free Report) was the target of a significant growth in short interest in the month of September. As of September 15th, there was short interest totalling 3,020,000 shares, a growth of 98.7% from the August 31st total of 1,520,000 shares. Approximately 14.4% of the shares of the stock are short sold. Based on an average trading volume of 6,040,000 shares, the days-to-cover ratio is currently 0.5 days.September 28, 2024 | marketbeat.com3 Penny Stocks to Watch Now, 9/18/24September 18, 2024 | msn.com Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address IMRX Media Mentions By Week IMRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. IMRX News Sentiment▼0.000.60▲Average Medical News Sentiment IMRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. IMRX Articles This Week▼12▲IMRX Articles Average Week Get Immuneering News Delivered to You Automatically Sign up to receive the latest news and ratings for IMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies FDMT News LFCR News CCCC News CRDF News SLRN News LRMR News OCGN News GNFT News INMB News MDWD News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:IMRX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immuneering Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immuneering With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMRX Stock Alerts